Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018 AHA/ACC Cholesterol Guidelines

Salim S. Virani, Julia M. Akeroyd, Sidney C. Smith, Mouaz Al-Mallah, Thomas M. Maddox, Pamela B. Morris, Laura A. Petersen, Christie M. Ballantyne, Scott M. Grundy, Neil J. Stone

Research output: Contribution to journalLetter

6 Scopus citations
Original languageEnglish (US)
Pages (from-to)712-714
Number of pages3
JournalJournal of the American College of Cardiology
Volume74
Issue number5
DOIs
StatePublished - Aug 6 2019

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Virani, S. S., Akeroyd, J. M., Smith, S. C., Al-Mallah, M., Maddox, T. M., Morris, P. B., Petersen, L. A., Ballantyne, C. M., Grundy, S. M., & Stone, N. J. (2019). Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018 AHA/ACC Cholesterol Guidelines. Journal of the American College of Cardiology, 74(5), 712-714. https://doi.org/10.1016/j.jacc.2019.05.051